We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Thermo Fisher (TMO) to Advance Clinical Research With New Pact
Read MoreHide Full Article
Thermo Fisher Scientific, Inc. (TMO - Free Report) recently collaborated with the National Minority Quality Forum (NMQF) to help bring clinical research to historically underserved patient populations through NMQF’s Alliance for Representative Clinical Trials (ARC).
More on the News
The collaboration reflects Thermo Fisher and NMQF's shared commitment to health equity and developing long-lasting solutions to involve groups and communities in the United States who have previously experienced structural and systemic inequity and/or have been denied access to clinical research for promising new medicines.
In addition to other ethnicities, veterans, people with disabilities, LGBTQ+ people, religious groups, people from disadvantaged socioeconomic backgrounds and geographical groups with unequal access to healthcare, these groups include African Americans, Asian Americans, Hispanics/Latinos and Native Americans and other ethnic groups.
The NMQF and Thermo Fisher's clinical research division will aid in increasing community health clinics' capacity to participate in clinical studies. Through systematic training and continuous involvement as investigator sites in clinical studies, the agreement will include ARC clinics in the clinical research process.
Significance of the Collaboration
The partnership helps biopharmaceutical and biotech clients meet regulatory requirements, such as those set forth by the FDA regarding diversity action plans, to enroll and retain clinical trial participants who more accurately represent real-world populations affected by the disease or health condition being studied.
The company is trying to develop clinical trials that reflect the different groups in society to serve its biopharma customers better, promote more significant health equity, and provide access to potentially life-changing medications. Additionally, addressing the need for a pipeline of skilled clinical research providers, NMQF highlights Thermo Fisher's commitment to empowering its customers to improve the health, safety, and cleanliness of the globe.
Image Source: Zacks Investment Research
Thermo Fisher's clinical research division's SiteCoach program offers community clinicians in the PI Institute and the MyClinical investigative site network customized support, training, and mentorship. Through the provision of advanced training to staff members in neighborhood clinics and practices who are new to clinical research, this support aids in extending access to trials and accelerating the development of novel medications.
Industry Prospects
Per a report by Grand View Research, the global clinical trials market size was valued at $49.8 billion in 2022 and is expected to expand at a CAGR of 5.8% by 2030. The market is expected to grow owing to factors such as the globalization of clinical trials, rapid technological evolution, and a rise in demand for CROs for conducting research activities.
Recent Developments
In August 2023, Thermo Fisher was granted a five-year award to provide a Transplantation Statistical and Clinical Coordinating Center for the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health in the United States. This center will offer a broad range of support services critical to the design, development, execution and analysis of NIAID transplantation clinical trials and research.
Thermo Fisher acquired CorEvitas the same month for $912.5 million in cash. The recent buyout advances world-class clinical research capabilities with a leading regulatory-grade registries platform.
Price Performance
In the past year, TMO shares have declined 10.5% compared with the industry’s fall of 6.8%.
Zacks Rank and Key Picks
Thermo Fisher currently carries a Zacks Rank #4 (Sell).
Haemonetics’ stock has risen 19.9% in the past year. Earnings estimates for Haemonetics have increased from $3.56 to $3.74 in 2023 and $3.96 to $4.07 in 2024 in the past 30 days. It currently carries Zacks Rank #2 (Buy).
HAE’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 19.39%. In the last reported quarter, it posted an earnings surprise of 38.16%
Estimates for Quanterix’s 2023 loss per share have narrowed from $1.19 to 97 cents in the past 30 days. Shares of the company have increased 167.5% in the past year against the industry’s decline of 1.7%. It currently carries Zacks Rank #2.
QTRX’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 30.39%. In the last reported quarter, it posted an earnings surprise of 55.56%.
Estimates for SiBone’s2023 loss have narrowed from $1.42 to $1.27 per share in the past 30 days. Shares of the company have increased 31% in the past year compared with the industry’s rise of 1.9%. It currently carries Zacks Rank #2 (Buy).
SIBN’s earnings beat estimates in all the trailing four quarters, the average surprise being 20.37%. In the last reported quarter, SiBone delivered an earnings surprise of 26.83%.
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Thermo Fisher (TMO) to Advance Clinical Research With New Pact
Thermo Fisher Scientific, Inc. (TMO - Free Report) recently collaborated with the National Minority Quality Forum (NMQF) to help bring clinical research to historically underserved patient populations through NMQF’s Alliance for Representative Clinical Trials (ARC).
More on the News
The collaboration reflects Thermo Fisher and NMQF's shared commitment to health equity and developing long-lasting solutions to involve groups and communities in the United States who have previously experienced structural and systemic inequity and/or have been denied access to clinical research for promising new medicines.
In addition to other ethnicities, veterans, people with disabilities, LGBTQ+ people, religious groups, people from disadvantaged socioeconomic backgrounds and geographical groups with unequal access to healthcare, these groups include African Americans, Asian Americans, Hispanics/Latinos and Native Americans and other ethnic groups.
The NMQF and Thermo Fisher's clinical research division will aid in increasing community health clinics' capacity to participate in clinical studies. Through systematic training and continuous involvement as investigator sites in clinical studies, the agreement will include ARC clinics in the clinical research process.
Significance of the Collaboration
The partnership helps biopharmaceutical and biotech clients meet regulatory requirements, such as those set forth by the FDA regarding diversity action plans, to enroll and retain clinical trial participants who more accurately represent real-world populations affected by the disease or health condition being studied.
The company is trying to develop clinical trials that reflect the different groups in society to serve its biopharma customers better, promote more significant health equity, and provide access to potentially life-changing medications. Additionally, addressing the need for a pipeline of skilled clinical research providers, NMQF highlights Thermo Fisher's commitment to empowering its customers to improve the health, safety, and cleanliness of the globe.
Thermo Fisher's clinical research division's SiteCoach program offers community clinicians in the PI Institute and the MyClinical investigative site network customized support, training, and mentorship. Through the provision of advanced training to staff members in neighborhood clinics and practices who are new to clinical research, this support aids in extending access to trials and accelerating the development of novel medications.
Industry Prospects
Per a report by Grand View Research, the global clinical trials market size was valued at $49.8 billion in 2022 and is expected to expand at a CAGR of 5.8% by 2030. The market is expected to grow owing to factors such as the globalization of clinical trials, rapid technological evolution, and a rise in demand for CROs for conducting research activities.
Recent Developments
In August 2023, Thermo Fisher was granted a five-year award to provide a Transplantation Statistical and Clinical Coordinating Center for the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health in the United States. This center will offer a broad range of support services critical to the design, development, execution and analysis of NIAID transplantation clinical trials and research.
Thermo Fisher acquired CorEvitas the same month for $912.5 million in cash. The recent buyout advances world-class clinical research capabilities with a leading regulatory-grade registries platform.
Price Performance
In the past year, TMO shares have declined 10.5% compared with the industry’s fall of 6.8%.
Zacks Rank and Key Picks
Thermo Fisher currently carries a Zacks Rank #4 (Sell).
Some better-ranked stocks in the broader medical space are Haemonetics (HAE - Free Report) , Quanterix (QTRX - Free Report) and SiBone (SIBN - Free Report) . You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Haemonetics’ stock has risen 19.9% in the past year. Earnings estimates for Haemonetics have increased from $3.56 to $3.74 in 2023 and $3.96 to $4.07 in 2024 in the past 30 days. It currently carries Zacks Rank #2 (Buy).
HAE’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 19.39%. In the last reported quarter, it posted an earnings surprise of 38.16%
Estimates for Quanterix’s 2023 loss per share have narrowed from $1.19 to 97 cents in the past 30 days. Shares of the company have increased 167.5% in the past year against the industry’s decline of 1.7%. It currently carries Zacks Rank #2.
QTRX’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 30.39%. In the last reported quarter, it posted an earnings surprise of 55.56%.
Estimates for SiBone’s2023 loss have narrowed from $1.42 to $1.27 per share in the past 30 days. Shares of the company have increased 31% in the past year compared with the industry’s rise of 1.9%. It currently carries Zacks Rank #2 (Buy).
SIBN’s earnings beat estimates in all the trailing four quarters, the average surprise being 20.37%. In the last reported quarter, SiBone delivered an earnings surprise of 26.83%.